Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

168.56USD
20 Jul 2018
Change (% chg)

$-0.06 (-0.04%)
Prev Close
$168.62
Open
$168.78
Day's High
$171.91
Day's Low
$168.20
Volume
109,235
Avg. Vol
190,363
52-wk High
$195.97
52-wk Low
$59.59

Latest Key Developments (Source: Significant Developments)

Sage Therapeutics Announces FDA Acceptance Of NDA Filing
Wednesday, 30 May 2018 

May 30 (Reuters) - SAGE Therapeutics Inc ::SAGE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NDA FILING AND GRANT OF PRIORITY REVIEW FOR BREXANOLONE IV IN THE TREATMENT OF POSTPARTUM DEPRESSION.SAGE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NDA FILING AND GRANT OF PRIORITY REVIEW FOR BREXANOLONE IV IN THE TREATMENT OF POSTPARTUM DEPRESSION.SAGE THERAPEUTICS INC - PRIORITY REVIEW STATUS EXPECTED TO ACCELERATE REVIEW PERIOD; PDUFA DATE SET FOR DECEMBER 19, 2018 FOR BREXANOLONE IV.SAGE THERAPEUTICS INC - FDA IS CURRENTLY PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS BREXANOLONE IV APPLICATION.  Full Article

Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression
Monday, 23 Apr 2018 

April 23 (Reuters) - SAGE Therapeutics Inc ::SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION.SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION.SAGE THERAPEUTICS - NDA SUBMISSION SUPPORTED BY DATA FROM HUMMINGBIRD PROGRAM.  Full Article

Sage Therapeutics Reports Positive Results From Phase 2 Placebo-Controlled Trial Of Sage-217 In Major Depressive Disorder
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Sage Therapeutics Inc ::SAGE THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 PLACEBO-CONTROLLED TRIAL OF SAGE-217 IN MAJOR DEPRESSIVE DISORDER.SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT AND PROVIDED RAPID, DURABLE EFFECTS THROUGH 2-WEEK TREATMENT PERIOD AND ADDITIONAL 4-WEEK FOLLOW-UP.SAGE THERAPEUTICS - PHASE 2 TRIAL OF SAGE-217​ ‍WELL-TOLERATED.SAGE THERAPEUTICS INC - DATA FROM PHASE 2 STUDY SUPPORT FURTHER DEVELOPMENT OF SAGE-217 FOR MDD AND RELATED DISORDERS.SAGE THERAPEUTICS - SAGE-217 DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT MEAN REDUCTION IN HAM-D SCORE COMPARED TO PLACEBO AT 15 DAYS​.SAGE THERAPEUTICS INC - SAGE-217 HAD NO SERIOUS OR SEVERE ADVERSE EVENTS IN PHASE 2 STUDY.SAGE THERAPEUTICS - ALL SECONDARY ENDPOINTS WERE CONSISTENT WITH PRIMARY ENDPOINTS AT DAY 15 OF TRIAL OF SAGE-217.  Full Article

Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Sage Therapeutics Inc -:SAGE THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE.  Full Article

Sage Therapeutics announces proposed public offering of common stock
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces proposed public offering of common stock.Sage Therapeutics Inc - ‍has commenced an underwritten public offering of $300.0 million of its common stock​.  Full Article

Sage Therapeutics announces Brexanolone achieves primary endpoints
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sage Therapeutics Inc ::Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression.Statistically significant mean reduction in HAM-D score compared to placebo at 60 hours demonstrated in both trials​.Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies​.Brexanolone achieved primary endpoint in both trials​.In each trial, 1 patient experienced serious adverse event; neither required hospitalization, 1 deemed not to be study-drug related​.Sage plans to file a New Drug Application (NDA) with U.S. Food and Drug Administration in 2018 for Brexanolone​.  Full Article

Sage Therapeutics announces qtrly loss per share $1.97‍​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update.Qtrly loss per share $1.97‍​.  Full Article

Sage Therapeutics advances SAGE-217
Monday, 13 Feb 2017 

Sage Therapeutics Inc - : Sage Therapeutics advances SAGE-217 into placebo-controlled phase 2 clinical trial in major depressive disorder . SAGE-217 was found to be generally well-tolerated with no serious adverse events or discontinuations reported .Statistically significant mean change from baseline was observed by day 2 of study.  Full Article

Sage Therapeutics starts Phase 2 clinical development for SAGE-217 in movement disorders
Tuesday, 13 Dec 2016 

Sage Therapeutics Inc : Essential tremor study is anticipated to report results in second half of 2017 . Sage Therapeutics announces initiation of Phase 2 clinical development for SAGE-217 in movement disorders . Sage Therapeutics - top-line results from part a open-label study in Parkinson's disease are expected in first half of 2017 .Also plans to initiate Phase 2 clinical trials of SAGE-217 in two mood disorders.  Full Article

Sage Therapeutics Q2 EPS ($1.08)
Tuesday, 9 Aug 2016 

Sage Therapeutics Inc : Sage Therapeutics announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $1.08.  Full Article

Photo

Rise in U.S. suicides highlights need for new depression drugs

CHICAGO A spike in suicide rates in the United States has cast fresh light on the need for more effective treatments for major depression, with researchers saying it is a tricky development area that has largely been abandoned by big pharmaceutical companies.